Linagliptin · Tradjenta

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
EU
  • Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment. as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. in...
Product first approved 2011EMA
JP
  • Treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to diet and exercise therapies alone)
Product first approved 2011PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Type 2 Diabetes
NCT04371978 · Rabin Medical Center
2020-10-01 – 2021-05-04 · COVID 19, Coronavirus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Dipeptidyl-Peptidase IV Inhibitors, Linagliptin, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Hypoglycemic Agents, Respiratory Tract Diseases, Incretins, Hormones
What this study did
NCT05290506 · National University of Malaysia
2020-08-01 – 2021-03-01 · PreDiabetes, Type 2 Diabetes
What this study did
NCT02851745 · Heart Care Foundation
2015-07 – 2019-07-02 · Diabetes Mellitus, Type 2, Left Ventricular Systolic Dysfunction
What this study did
NCT02752113 · Institut für Pharmakologie und Präventive Medizin
2016-04 – 2019-05 · Diabetes Mellitus Type 2
What this study did
NCT02897349 · Boehringer Ingelheim
2016-09-30 – 2019-01-18 · Diabetes Mellitus, Type 2
What this study did
NCT02489968 · Boehringer Ingelheim
2015-05-12 – 2017-06-16 · Diabetes Mellitus, Type 2
What this study did
NCT02015299 · dr. DJ Mulder
2014-03 – 2016-03 · Type 2 Diabetes Mellitus
What this study did
NCT01792518 · Boehringer Ingelheim
2013-02 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT02077309 · RWTH Aachen University
2014-08 – 2015-11 · Diabetes Mellitus Type 2 (T2DM), Vascular Inflammation, Plaque Morphology
What this study did
NCT01734785 · Boehringer Ingelheim
2013-02-08 – 2015-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT01888796 · RWTH Aachen University
2013-09 – 2014-12 · Diabetes Mellitus Type 2 (T2DM), Left Ventricular Diastolic Dysfunction
What this study did
NCT01708902 · Boehringer Ingelheim
2012-10 – 2014-04 · Diabetes Mellitus, Type 2
What this study did
NCT01835678 · University of Erlangen-Nürnberg Medical School
2012-10 – 2014-04 · Type 2-diabetes
What this study did
NCT01087502 · Boehringer Ingelheim
2010-03 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT00996658 · Boehringer Ingelheim
2009-10 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01204294 · Boehringer Ingelheim
2010-09 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT01194830 · Boehringer Ingelheim
2010-09 – 2011-10 · Diabetes Mellitus, Type 2
What this study did
NCT00954447 · Boehringer Ingelheim
2009-08 – 2011-09 · Diabetes Mellitus, Type 2
What this study did
NCT01084005 · Boehringer Ingelheim
2010-03 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT00915772 · Boehringer Ingelheim
2009-06 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT00800683 · Boehringer Ingelheim
2008-12 – 2011-01 · Diabetes Mellitus, Type 2
What this study did
NCT00641043 · Boehringer Ingelheim
2008-03 – 2009-06 · Diabetes Mellitus, Type 2
What this study did
NCT00621140 · Boehringer Ingelheim
2008-02 – 2009-05 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04542213 · Hospital Regional de Alta Especialidad del Bajio
2020-08-01 – 2021-02-28 · Hyperglycemia, Covid19
What this study did
NCT04131582 · Universidad de Guanajuato
2019-09-01 – 2020-12-30 · Prediabetic State, Insulin Resistance
What this study did
NCT04134650 · Universidad de Guanajuato
2019-09-01 – 2020-07-01 · Prediabetic State, Insulin Resistance
What this study did
NCT03051243 · Rabin Medical Center
2017-10-01 – 2019-11-01 · DM2
What this study did
NCT02376075 · ikfe-CRO GmbH
2013-01 – 2014-09 · Arterial Hypertension, Albuminuria
What this study did
Phase 2 (7)
Type 2 Diabetes
NCT03986073 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-01-01 – 2020-09-30 · Type 2 Diabetes Mellitus
What this study did
NCT03667300 · Samsung Medical Center
2017-03-16 – 2019-05-14 · Type2 Diabetes Mellitus, Albuminuria, Renal Insufficiency
What this study did
NCT01342484 · Boehringer Ingelheim
2011-04 – 2016-02 · Diabetes Mellitus, Type 2
What this study did
NCT01012037 · Boehringer Ingelheim
2009-11 – 2010-09 · Diabetes Mellitus, Type 2
What this study did
NCT00716092 · Boehringer Ingelheim
2008-07 – 2008-11 · Diabetes Mellitus, Type 2
What this study did
NCT00309608 · Boehringer Ingelheim
2006-04 – 2007-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04662866 · Oslo University Hospital
2021-02-10 – 2023-10 · Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03281369 · Hoffmann-La Roche
2017-10-13 – 2025-10-09 · Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
What this study did
Phase 1 (41)
Type 2 Diabetes
NCT07872358 · Humanis Saglık Anonim Sirketi
2026-06-07 – 2026-10-07 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07691203 · Humanis Saglık Anonim Sirketi
2026-03-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07034781 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT07044765 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT06932159 · Humanis Saglık Anonim Sirketi
2024-12-23 – 2025-04-08 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01383356 · Boehringer Ingelheim
2011-06 – 2011-12 · Diabetes Mellitus, Type 2
What this study did
NCT00935220 · Boehringer Ingelheim
2009-06 – 2010-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06243809 · International Bio service
2024-04-24 – 2024-07-02 · Healthy Volunteer
What this study did
NCT05874180 · Dong Wha Pharmaceutical Co. Ltd.
2023-01-09 – 2023-02-03 · Healthy Subjects
What this study did
NCT05956522 · The Affiliated Hospital of Qingdao University
2022-07-01 – 2023-01-13 · Healthy
What this study did
NCT05874167 · Dong Wha Pharmaceutical Co. Ltd.
2022-08-08 – 2022-10-11 · Healthy Subjects
What this study did
NCT03609294 · Boryung Pharmaceutical Co., Ltd
2018-07-18 – 2019-06-30 · Hypertension, Diabetes
What this study did
NCT01943019 · Monash University
2013-08 – 2018-08 · Schizophrenia
What this study did
NCT03250052 · Boryung Pharmaceutical Co., Ltd
2017-08-14 – 2017-11-21 · Hypertension
What this study did
NCT02821910 · Boehringer Ingelheim
2016-07-20 – 2016-10-31 · Healthy
What this study did
NCT02815644 · Boehringer Ingelheim
2016-07-15 – 2016-10-05 · Healthy
What this study did
NCT02212782 · Dong Wha Pharmaceutical Co. Ltd.
2014-09 – 2015-01 · Healthy
What this study did
NCT02121509 · Boehringer Ingelheim
2014-05 – 2014-07 · Healthy
What this study did
NCT02084056 · Boehringer Ingelheim
2014-04 – 2014-07 · Healthy
What this study did
NCT02084082 · Boehringer Ingelheim
2014-04 – 2014-07 · Healthy
What this study did
NCT01947153 · Boehringer Ingelheim
2013-11 – 2014-01 · Healthy
What this study did
NCT01845077 · Boehringer Ingelheim
2013-05 – 2013-08 · Healthy
What this study did
NCT01540487 · Boehringer Ingelheim
2012-02 – 2012-06 · Healthy
What this study did
NCT01276327 · Boehringer Ingelheim
2011-01 – 2011-05 · Healthy
What this study did
NCT01189201 · Boehringer Ingelheim
2010-08 – 2010-11 · Healthy
What this study did
NCT02183584 · Boehringer Ingelheim
2009-09 – 2009-10 · Healthy
What this study did
NCT02172222 · Boehringer Ingelheim
2009-07 – 2009-09 · Healthy
What this study did
NCT02183480 · Boehringer Ingelheim
2009-07 – 2009-09 · Healthy
What this study did
Phase 4 (33)
Type 2 Diabetes
NCT07452913 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06862739 · Nabiqasim Industries (Pvt) Ltd
2025-10-30 – 2026-06-30 · Diabetes Mellitus, Type 2 DM
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT03433248 · M.H.H. Kramer
2017-11-09 – 2022-09-01 · Type2 Diabetes
What this study did
NCT04341935 · University of Miami
2021-06-30 – 2021-12-30 · Coronavirus Infection, Type 2 Diabetes
What this study did
NCT03320031 · Yanbing Li
2017-06-03 – 2019-12 · Type 2 Diabetes Mellitus, Peritoneal Dialysis
What this study did
NCT02467478 · George Washington University
2015-04 – 2019-12 · Type 2 Diabetes, Impaired Renal Function
What this study did
NCT02372630 · University at Buffalo
2014-05-23 – 2018-05-01 · Type 2 Diabetes
What this study did
NCT01897532 · Boehringer Ingelheim
2013-07-10 – 2018-01-18 · Diabetes Mellitus, Type 2
What this study did
NCT02240680 · Boehringer Ingelheim
2014-09-23 – 2017-04-25 · Diabetes Mellitus, Type 2
What this study did
NCT02004366 · Emory University
2014-01 – 2017-03 · Type 2 Diabetes
What this study did
NCT02350478 · Medical University of Graz
2013-07 – 2017-03 · Type 2 Diabetes, Coronary Artery Disease
What this study did
NCT02280174 · Ministry of Public Health, Argentina
2014-09 – 2016-10 · Type 2 Diabetes
What this study did
NCT02092597 · Charles University, Czech Republic
2013-10 – 2016-09 · Type 2 Diabetes Mellitus
What this study did
NCT01969084 · Beth Israel Deaconess Medical Center
2013-10 – 2016-07 · Type II Diabetes Mellitus
What this study did
NCT02106104 · Amsterdam UMC, location VUmc
2014-03 – 2016-04 · Type 2 Diabetes
What this study did
NCT02401880 · Profil Institut für Stoffwechselforschung GmbH
2015-05 – 2015-12 · Type 2 Diabetes Mellitus
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT02097342 · Post Graduate Institute of Medical Education and Research, Chandigarh
2013-12 – 2015-01 · Type 2 Diabetes Mellitus, Insulin Sensitivity/Resistance
What this study did
NCT01617824 · University of Padova
2012-09 – 2014-12 · Type 2 Diabetes, Chronic Renal Failure
What this study did
NCT01512979 · Boehringer Ingelheim
2012-01 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01438814 · Boehringer Ingelheim
2011-11 – 2013-03 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07247656 · Bahria University
2022-12-01 – 2023-05-01 · Diabete Mellitus
What this study did
NCT05200793 · Alexandria University
2021-12-07 – 2022-09-01 · Polycystic Ovary Syndrome (PCOS)
What this study did
NCT03504566 · Steno Diabetes Center Copenhagen
2017-11-15 – 2019-06-01 · Diabetic Nephropathy Type 2
What this study did
NCT03004612 · Universidad de Guanajuato
2016-01 – 2019-06 · Prediabetic State, Insulin Resistance
What this study did
NCT03642184 · RenJi Hospital
2018-07-14 – 2019-01-31 · New Onset Diabetes After Transplant, Kidney Transplant; Complications
What this study did
NCT02768220 · Northwell Health
2017-12-01 – 2018-12 · SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
What this study did
NCT04088461 · Universidad de Guanajuato
2016-09 – 2018-09 · Prediabetic State, Impaired Glucose Tolerance, Insulin Resistance
What this study did
NCT02442817 · University of Nevada, Reno
2015-03-02 – 2018-03-02 · Schizophrenia
What this study did
NCT02061969 · Emory University
2014-04-25 – 2017-04-10 · Diabetes
What this study did
NCT01903070 · Profil Institut für Stoffwechselforschung GmbH
2013-07-11 – 2016-04 · Diabetes Mellitus
What this study did
Early phase / not applicable (5)
Type 2 Diabetes
NCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-10-08 – 2026-07-01 · Type 2 Diabetes Mellitus, Mild Cognitive Impairment
What this study did
NCT02608177 · University of Washington
2015-11 – 2018-08 · Chronic Kidney Diseases, Type 2 Diabetes
What this study did
NCT02792400 · University Hospital, Gentofte, Copenhagen
2016-05 – 2018-07 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT03222765 · Evidem Consultores SL
2015-03-15 – 2019-12-31 · PreDiabetes
What this study did
NCT02725502 · Post Graduate Institute of Medical Education and Research, Chandigarh
2013-07 – 2016-05 · Type 1 Diabetes Mellitus
What this study did
Used as active comparator (15)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Type 2 Diabetes
NCT04670666 · EMS
2024-11-18 – 2027-06 · Type 2 Diabetes Mellitus
What this study did
NCT05886088 · EMS
2024-02 – 2027-01 · Type 2 Diabetes Mellitus
What this study did
NCT03766750 · EMS
2021-12 – 2023-11 · Type2 Diabetes Mellitus
What this study did
NCT04564872 · Sichuan Haisco Pharmaceutical Group Co., Ltd
2020-11-13 – 2022-08-29 · Diabetes Mellitus, Type 2
What this study did
NCT02453555 · Boehringer Ingelheim
2015-05-14 – 2017-03-27 · Diabetes Mellitus, Type 2
What this study did
NCT01422876 · Boehringer Ingelheim
2011-08 – 2013-09 · Diabetes Mellitus, Type 2
What this study did
Phase 4 (6)
Type 2 Diabetes
NCT07442006 · JW Pharmaceutical
2025-10-29 – 2027-03-31 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07019012 · Huazhong University of Science and Technology
2025-07-30 – 2026-12-30 · T2DM
What this study did
NCT03458715 · Mackay Memorial Hospital
2017-09-21 – 2018-11-21 · Type2 Diabetes
What this study did
NCT03011177 · Handok Inc.
2017-01 – 2018-09 · Type2 Diabetes Mellitus
What this study did
NCT02974504 · Dong-A ST Co., Ltd.
2016-09 – 2018-03 · Type2 Diabetes
What this study did
Other / comorbidity
NCT02429232 · National Taiwan University Hospital
2015-10 – 2017-12 · Osteoporosis, Diabetes Mellitus
What this study did
Early phase / not applicable (3)
Type 2 Diabetes
NCT07786571 · Sun Yat-sen University
2026-12-01 – 2029-07-01 · Type 2 Diabetes Mellitus (T2DM), Chronic Renal Insufficiency, Chronic Kidney Disease (Stages 3b-5), Glucose Homeostasis
What this study did
Other / comorbidity
NCT06098625 · Medanta, The Medicity, India
2023-11-10 – 2025-12-01 · Diabetes Mellitus, Kidney Transplant; Complications
What this study did
NCT06095492 · Medanta, The Medicity, India
2023-10-30 – 2025-12-01 · Kidney Transplant; Complications, Diabetes Mellitus
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 1 (1)
Other / comorbidity
NCT05066516 · Korea University Anam Hospital
2020-06-25 – 2020-10-18 · Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Type 2 Diabetes
NCT02180334 · Seoul National University Hospital
2014-07 – 2015-04 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Linagliptin (Tradjenta): this drugApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Omarigliptin (Marizev)
Phase 3(overall)
Small moleculeDPP-4
Reliable signal(overall)
NCT01755156: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) (Baseline and Week 24): Omarigliptin (Phase A) -0.54 Percent (95% CI -0.69 to -0.4) vs Placebo to Omarigliptin (Phase A) 0 Percent (95% CI -0.14 to 0.15)
NCT01698775: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Baseline and Week 24): Omarigliptin (Phase A) -0.77 Percent (95% CI -1 to -0.54) vs Placebo to Omarigliptin (Phase A) -0.44 Percent (95% CI -0.67 to -0.21)
Prusogliptin (Shanzeping)Phase 3Small moleculeDPP-4Reliable signal
NCT04161430: HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo.
NCT04218734: Change in HbA1c at week 24: −0.70% (DBPR108 + metformin) vs −0.07% (placebo + metformin); upper limit of the 95% CI for the between-group difference was −0.39, below the 0% superiority margin (P < .001).
RetagliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Teneligliptin (Tenelia)Phase 3Small moleculeDPP-4Partial signal
NCT01805830: Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL).
NCT01798238: Change in HbA1c at week 24, teneligliptin 20mg vs placebo: difference -0.94% (LS mean 95% CI -1.22, -0.65), p<0.001; fasting plasma glucose difference -1.21 mmol/L (95% CI -1.72, -0.70), p<0.001.
Trelagliptin (Zafatek)Phase 3Small moleculeDPP-4Weak signal
NCT02512068: Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089)
NCT02324569: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) (End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)): Treatment Group I -0.56% ± 0.070 vs Treatment Group II 0.07% ± 0.067; p=<0.0001 (Treatment Group I vs Treatment Group II)
Vildagliptin (Galvus)Phase 3Small moleculeDPP-4Partial signal
NCT00099866: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) missed
YogliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Retagliptin / Metformin (Ruilintang)Phase 1Small moleculeDPP-4, AMPKPartial signalNo reviewed efficacy summary in this indication

Large race: only the 76 furthest-along competitors are listed; 75 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

No upcoming readouts on record for this asset.